Table 1

Baseline characteristics of the csDMARD tapering group and the TNF inhibitor tapering group

CharacteristicsTapering csDMARD (n=94)Tapering TNF inhibitor (n=95)
Demographic
 Age (years), mean (95% CI)55.9 (53.0 to 58.8)57.2 (55.0 to 59.4)
 Gender, female, n (%)67 (71)58 (61)
Disease characteristics
 Symptom duration (years), median (IQR)6.0 (4.1–8.5)6.4 (4.2–8.9)
 RF positive, n (%)50 (57)59 (65)
 ACPA positive, n (%)62 (71)67 (75)
Disease activity
 DAS44, mean (95% CI)1.1 (0.9 to 1.2)1.0 (0.9 to 1.1)
 DAS clinical remission, DAS44 <1.6, n (%)76 (81)87 (88)
 TJC44, median (IQR)0 (0–2)0 (0–1)
 SJC44, median (IQR)0 (0–0)0 (0–0)
 VAS disease activity (0–100 mm), median (IQR)20 (4–32)12 (4–23)
 ESR in mm/hour, median (IQR)8 (3–14)8 (2–15)
 CRP in mg/L, median (IQR)2.2 (1–5)2 (1–6)
Use of csDMARDs*
 MTX, n (%)90 (96)84 (88)
 SASP, n (%)10 (11)12 (13)
 HCQ, n (%)24 (26)37 (39)
 Leflunomide, n (%)2 (2)4 (4)
Use of TNF inhibitor
 Etanercept, n (%)51 (54)52 (55)
 Adalimumab, n (%)37 (39)40 (42)
 Others, n (%)†6 (6)3 (3)
Radiographs (hand/foot)
 mTSS (0–488), median (IQR)2 (0–6.5)1 (0–3.5)
 Erosion score (0–280), median (IQR)0 (0–2.5)0 (0–2)
 JSN score (0–168), median (IQR)0.5 (0–2.5)0 (0–2.5)
 Erosive disease, n(%)‡37 (39)26 (27)
Patient-reported outcomes
 HAQ-DI, mean (95% CI)0.52 (0.42 to 0.62)0.47 (0.35 to 0.58)
 SF-36, median (IQR)
  PCS43 (29–48)47 (39–51)
  MCS60 (56–63)57 (51–62)
 EQ-5D index, mean (95% CI)0.86 (0.83 to 0.88)0.87 (0.85 to 0.89)
  • *Some patients used a combination of csDMARDs.

  • †Certolizumab or golimumab.

  • ‡Erosive disease is characterised as having >1 erosion in three separate joints.

  • ACPA, anticitrullinated protein antibody;CRP, C reactive protein;csDMARD, conventional synthetic disease-modifying antirheumatic drug;DAS44, Disease Activity Score Measured in 44 joints;EQ5D, European Quality of Life-5 Dimensions;ESR, erythrocyte sedimentation rate;HAQ-DI, Health Assessment Questionnaire Disability Index;HCQ, hydroxychloroquine;JSN, joint space narrowing;MCS, mental component summary;mTSS, modified Sharp/Van der Heijde score.MTX, methotrexate;PCS, physical component summary;RF, rheumatoid factor;SASP, sulfasalazine;SF-36, Short Form-36;SJC, Swollen Joint Count;TJC, Tender Joint Count;VAS, Visual Analogue Scale;